SynthesisFrontiers in oncology2026
CircZNF609 as a potential prognostic biomarker across multiple cancers: a systematic review and meta-analysis with ceRNA network exploration.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CircZNF609 (hsa_circ_0000615), a back-spliced transcript derived from the ZNF609 gene locus, has garnered increasing attention for its functional roles in tumor progression across multiple cancer types. However, no pan-cancer meta-analysis has systematically evaluated its prognostic value and association with clinicopathological aggressiveness. We therefore performed this systematic review and meta-analysis to synthesize all available clinical evidence addressing this critical gap. Methods: We systematically retrieved literature from five databases (PubMed, Web of Science, Embase, the Cochrane Library and CNKI) up to April 2, 2026. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were synthesized to quantify the link between circZNF609 levels and overall survival (OS) or clinicopathological variables. Heterogeneity assessment, sensitivity analysis, and publication bias evaluation were also performed. Additionally, a circZNF609-mediated ceRNA network was reconstructed based on experimentally validated targets. Results: A total of 12 studies involving 791 patients were included in this meta-analysis. Elevated circZNF609 expression was significantly associated with worse overall survival (HR = 2.31, 95% CI:1.74-3.07, Conclusions: Increased circZNF609 expression is associated with adverse survival outcomes and aggressive clinicopathological behavior across multiple malignancies. The ceRNA network offers mechanistic support for these clinical associations. CircZNF609 warrants validation in prospective, multi-ethnic cohorts as a promising prognostic biomarker and candidate therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.